Wall Street Zen Downgrades Sensus Healthcare (NASDAQ:SRTS) to Sell

Sensus Healthcare (NASDAQ:SRTS) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

SRTS has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research note on Thursday, January 22nd. Zacks Research upgraded shares of Sensus Healthcare from a “strong sell” rating to a “hold” rating in a research report on Wednesday, October 22nd. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $8.00.

Sensus Healthcare Price Performance

Shares of NASDAQ:SRTS opened at $3.86 on Friday. Sensus Healthcare has a 12 month low of $3.03 and a 12 month high of $5.92. The stock has a market cap of $63.38 million, a price-to-earnings ratio of -8.21 and a beta of 1.21. The stock’s 50 day moving average price is $4.46 and its 200 day moving average price is $3.93.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.10). Sensus Healthcare had a negative net margin of 28.09% and a negative return on equity of 14.82%. The firm had revenue of $4.94 million for the quarter, compared to the consensus estimate of $8.35 million. On average, sell-side analysts expect that Sensus Healthcare will post 0.32 EPS for the current year.

Insider Activity

In other news, CEO Joseph C. Sardano bought 25,000 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were acquired at an average cost of $4.03 per share, with a total value of $100,750.00. Following the completion of the transaction, the chief executive officer directly owned 1,200,293 shares in the company, valued at approximately $4,837,180.79. The trade was a 2.13% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Eric Sachetta purchased 7,000 shares of the business’s stock in a transaction dated Friday, November 21st. The shares were purchased at an average price of $3.93 per share, for a total transaction of $27,510.00. Following the acquisition, the director directly owned 140,113 shares of the company’s stock, valued at $550,644.09. This trade represents a 5.26% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have acquired 33,000 shares of company stock worth $132,060. Corporate insiders own 8.90% of the company’s stock.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds have recently modified their holdings of the stock. State Street Corp raised its holdings in shares of Sensus Healthcare by 5.2% during the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock valued at $276,000 after purchasing an additional 3,400 shares in the last quarter. Geode Capital Management LLC increased its stake in Sensus Healthcare by 2.5% in the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock valued at $730,000 after acquiring an additional 3,766 shares during the period. Sachetta LLC raised its holdings in shares of Sensus Healthcare by 6.8% in the 4th quarter. Sachetta LLC now owns 148,508 shares of the company’s stock worth $591,000 after buying an additional 9,500 shares in the last quarter. Vise Technologies Inc. acquired a new position in Sensus Healthcare during the second quarter worth $52,000. Finally, Mindset Wealth Management LLC increased its position in shares of Sensus Healthcare by 28.1% during the 3rd quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock worth $157,000 after purchasing an additional 11,000 shares in the last quarter. 25.30% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Sensus Healthcare

Here are the key news stories impacting Sensus Healthcare this week:

• Positive Sentiment: Publication of dedicated CPT codes for superficial radiation therapy (SRT) to treat non‑melanoma skin cancer — a potential boost to reimbursement and broader adoption that could improve unit economics over time. Business Wire: Q4 2025 Results & CPT Codes
• Positive Sentiment: Management is explicitly targeting profitability in 2026 by expanding reimbursement, diversifying the customer base and driving adoption — a constructive strategic path if execution and reimbursement traction continue. Seeking Alpha: Profitability Target 2026
• Neutral Sentiment: Earnings call transcripts and highlights show management discussing reimbursement progress and operating initiatives; no material upside guidance was issued to offset the quarter’s miss. Useful for detail but did not reverse market reaction. MSN: Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($0.19) vs. consensus (~($0.09)) and revenue $4.94M vs. ~$8.35M consensus; the company reported a quarterly net loss and negative margins — a near‑term catalyst for selling pressure. Company Press Release: Q4 2025 Results
• Negative Sentiment: Longer‑term shareholder returns have been weak (article notes a ~36% loss over three years), underscoring investor sensitivity to execution and growth consistency. Yahoo Finance: Shareholder Returns

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.